Prenetics will release Q1 2026 financial results on May 14, followed by a conference call at 10 a.m. ET.
Quiver AI Summary
Prenetics Global Limited, the parent company of the premium health brand IM8 co-founded by David Beckham, announced it will release its financial results for the first quarter of 2026 on May 14, 2026, prior to the market opening. An earnings conference call is scheduled for the same day at 10:00 a.m. Eastern Time, where the results will be discussed in detail and followed by a Q&A session for analysts. IM8 has quickly become a leader in the health and nutrition sector with its flagship product, Daily Ultimate Essentials, achieving over $100 million in annualized recurring revenue within 11 months and being sold in more than 40 countries. The brand is well-regarded by athletes like Giannis Antetokounmpo and Aryna Sabalenka.
Potential Positives
- Announcement of first quarter 2026 financial results expected to provide insights into the company's performance.
- IM8 has achieved over $100 million in annualized recurring revenue within 11 months, indicating strong market demand and growth.
- IM8 is now sold in more than 40 countries, highlighting significant global market expansion.
- The association with high-profile co-founders and endorsements from top athletes enhances the brand's credibility and visibility.
Potential Negatives
- There is no mention of profitability or potential challenges in achieving financial growth, which could raise concerns among investors about the company's overall financial health.
FAQ
When will Prenetics release its Q1 2026 financial results?
Prenetics will release its financial results for Q1 2026 on May 14, 2026, before market open.
What time is the Prenetics earnings conference call?
The earnings conference call will take place at 10:00 a.m. Eastern Time on May 14, 2026.
How can I listen to the Prenetics conference call?
Dial-in details for the conference call are 1-877-425-9470 for the U.S. and 1-201-389-0878 internationally.
What is IM8 and who co-founded it?
IM8 is a premium health brand co-founded by David Beckham and a team of elite scientists.
Where can I find more information about IM8?
More information about IM8 can be found on their website at www.IM8health.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PRE Hedge Fund Activity
We have seen 25 institutional investors add shares of $PRE stock to their portfolio, and 6 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANE STREET GROUP, LLC added 82,681 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,302,225
- 683 CAPITAL MANAGEMENT, LLC added 75,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $1,181,250
- ABERDEEN GROUP PLC removed 73,621 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,159,530
- MILLENNIUM MANAGEMENT LLC added 51,432 shares (+inf%) to their portfolio in Q4 2025, for an estimated $810,054
- MARSHALL WACE, LLP added 50,025 shares (+inf%) to their portfolio in Q4 2025, for an estimated $787,893
- NOMURA HOLDINGS INC removed 48,998 shares (-15.5%) from their portfolio in Q4 2025, for an estimated $771,718
- QUBE RESEARCH & TECHNOLOGIES LTD added 31,144 shares (+inf%) to their portfolio in Q4 2025, for an estimated $490,518
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Full Release
NEW YORK, May 08, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), the parent company of IM8, the premium health and longevity brand co-founded with David Beckham, today announced it will release financial results for the first quarter 2026 ended March 31, 2026 before market open on Thursday, May 14, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
| Date: | Thursday, May 14, 2026 |
| Time: | 8:30 a.m. Eastern Time |
| Dial-in: | 1-877-425-9470 |
| International Dial-in: | 1-201-389-0878 |
| Webcast | PRE Conference Call |
An audio replay of the webcast will be available on the Company’s investor relations website at
https://ir.prenetics.com/
.
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. IM8’s flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is trusted by NBA Champion and two-time MVP Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka, and F1 driver Ollie Bearman. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within just 11 months and is now sold in more than 40 countries worldwide. IM8 is a subsidiary of Prenetics (NASDAQ: PRE). To learn more, visit www.IM8health.com.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and trusted by NBA superstar Giannis Antetokounmpo, World No. 1 tennis player Aryna Sabalenka and F1 phenom Ollie Bearman, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, achieving an impressive milestone of surpassing $100 million in annualized recurring revenue within just 11 months of operations, and is now sold in more than 40 countries worldwide.
Investor Relations Contact:
[email protected]
[email protected]
Angela Cheung
Investor Relations / Corporate Finance
[email protected]
